Mariner
HRTX icon

Mariner’s Heron Therapeutics HRTX Stock Holding History

Mariner’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.3K Buy
35,353
+16,354
+86% +$19K ﹤0.01% 3475
2025
Q4 		$24.7K Sell
18,999
-16,900
-47% -$20.9K ﹤0.01% 3469
2025
Q3 		$45.2K Buy
+35,899
New +$56.9K ﹤0.01% 3461

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Mariner's HRTX Position: Q1 2026 in Review

Mariner increased its Heron Therapeutics (HRTX) stake by 86% in Q1 2026, buying an estimated $19K and bringing the position to 35,353 shares worth $28.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3475.

Mariner first reported a position in HRTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $45.2K in Q3 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Mariner held 35,353 shares of Heron Therapeutics worth $28.3K as of Q1 2026.
  • Mariner bought 16,354 Heron Therapeutics shares in Q1 2026, an estimated $19K.
  • Heron Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #3475 holding.
  • Mariner first reported a position in Heron Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Mariner's Heron Therapeutics position peaked at $45.2K in Q3 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.